Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients

European Journal of Cancer, Supplement

Volumn 5, Issue 2, 2007, Pages 49-59

  Herbrecht, Raoul ^a   Flückiger, Ursula ^b   Gachot, Bertrand ^c   Ribaud, Patricia ^d   Thiebaut, Anne ^e   Cordonnier, Catherine ^f  

^a HÔPITAL DE HAUTEPIERRE   (France)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e EDOUARD HERRIOT HOSPITAL   (France)

^f HENRI MONDOR HOSPITAL   (France)

Author keywords

Antifungal therapy; Aspergillosis; Candidaemia; Invasive candidiasis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; PYRROLE; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; ARTICLE; ASPERGILLOSIS; BONE MARROW TRANSPLANTATION; CANDIDA ALBICANS; CANDIDIASIS; CHILL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; EUROPE; FEVER; FUNGAL STRAIN; HUMAN; HYPOKALEMIA; HYPOTENSION; HYPOXEMIA; IMMUNOCOMPROMISED PATIENT; INFECTION CONTROL; LEUKEMIA; MEDICAL PRACTICE; MYCOSIS; NEPHROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 34547513219     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcsup.2007.06.007     Document Type: Article

References (84)

1. Herbrecht R., Denning D.W., Patterson T.F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347 (2002) 408-415
2. Kullberg B.J., Sobel J.D., Ruhnke M., et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 366 (2005) 1435-1442
3. Dykewicz C.A. Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. Clin Infect Dis 33 (2001) 139-144
4. Abi-Said D., Anaissie E., Uzun O., Raad I., Pinzcowski H., and Vartivarian S. The epidemiology of haematogenous candidiasis caused by different Candida species. Clin Infect Dis 24 (1997) 1122-1128
5. Viscoli C., Girmenia C., Marinus A., et al. Candidaemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 28 (1999) 1071-1079
6. Wingard J.R., Merz W.G., Rinaldi M.G., Johnson T.R., Karp J.E., and Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 325 (1991) 1274-1277
7. White M.H. The contribution of fluconazole to the changing epidemiology of invasive candidal infections. Clin Infect Dis 24 (1997) 1129-1130
8. Ostrosky-Zeichner L., Rex J.H., Pappas P.G., et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 47 (2003) 3149-3154
9. Malani A., Hmoud J., Chiu L., Carver P.L., Bielaczyc A., and Kauffman C.A. Candida glabrata fungemia: experience in a tertiary care center. Clin Infect Dis 41 (2005) 975-981
10. Walsh T.J., Finberg R.W., Arndt C., et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 340 (1999) 764-771
11. Eriksson U., Seifert B., and Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 322 (2001) 579-582
12. Furrer K., Schaffner A., Vavricka S.R., Halter J., Imhof A., and Schanz U. Nephrotoxicity of cyclosporine A and amphotericin B-deoxycholate as continuous infusion in allogenic stem cell transplantation. Swiss Med Wkly 132 (2002) 316-320
13. Imhof A., Walter R.B., and Schaffner A. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin Infect Dis 36 (2003) 943-951
14. Peleg A.Y., and Woods M.L. Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients. J Antimicrob Chemother 54 (2004) 803-808
15. Leenders A.C., Daenen S., Jansen R.L., et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 103 (1998) 205-212
16. Noskin G.A., Pietrelli L., Coffey G., Gurwith M., and Liang L.J. Amphotericin B colloidal dispersion for treatment of candidaemia in immunocompromised patients. Clin Infect Dis 26 (1998) 461-467
17. Ito J.I., and Hooshmand-Rad R. Treatment of Candida infections with amphotericin B lipid complex. Clin Infect Dis 40 Suppl 6 (2005) S384-S391
18. Anaissie E.J., Darouiche R.O., Abi-Said D., et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 23 (1996) 964-972
19. Anaissie E.J., Vartivarian S.E., Abi-Said D., et al. Fluconazole versus amphotericin B in the treatment of haematogenous candidiasis: a matched cohort study. Am J Med 101 (1996) 170-176
20. Anaissie E.J., Rex J.H., Uzun O., and Vartivarian S. Predictors of adverse outcome in cancer patients with candidaemia. Am J Med 104 (1998) 238-245
21. Phillips P., Shafran S., Garber G., et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidaemia in non-neutropenic patients. Canadian Candidaemia Study Group. Eur J Clin Microbiol Infect Dis 16 (1997) 337-345
22. Rex J.H., Bennett J.E., Sugar A.M., et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidaemia in patients without neutropenia. Candidaemia Study Group and the National Institute. N Engl J Med 331 (1994) 1325-1330
23. Ostrosky-Zeichner L., Oude Lashof A.M., Kullberg B.J., and Rex J.H. Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 22 (2003) 651-655
24. Walsh T.J., Pappas P., Winston D.J., et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346 (2002) 225-234
25. Mora-Duarte J., Betts R., Rotstein C., et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347 (2002) 2020-2029
26. Walsh T.J., Teppler H., Donowitz G.R., et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351 (2004) 1391-1402
27. DiNubile M.J., Hille D., Sable C.A., and Kartsonis N.A. Invasive candidiasis in cancer patients: observations from a randomized clinical trial. J Infect 50 (2005) 443-449
28. Ruhnke M, Kuse E, Chetchotisakd P, Arns da Cunha C, Diekmann-Berndt H. Comparison of micafungin and liposomal amphotericin B for invasive candidiasis. In: Proceeding of the 45th interscience conference on antimicrobial agents and chemotherapy, Washington (DC), December 16-19; 2005 [Abstract M-722c].
29. Reboli A, Rotstein C, Pappas P, Schranz J, Krause D, Walsh T. Anidulafungin vs. fluconazole for treatment of candidaemia and invasive candidiasis. In: Proceeding of the 45th interscience conference on antimicrobial agents and chemotherapy, Washington (DC), December 16-19; 2005 [Abstract M718].
30. Pappas P.G., Rex J.H., Sobel J.D., et al. Guidelines for treatment of candidiasis. Clin Infect Dis 38 (2004) 161-189
31. Nucci M., and Anaissie E. Should vascular catheters be removed from all patients with candidaemia? An evidence-based review. Clin Infect Dis 34 (2002) 591-599
32. Raad I., Hanna H., Boktour M., et al. Management of central venous catheters in patients with cancer and candidaemia. Clin Infect Dis 38 (2004) 1119-1127
33. SFAR, SPILF, SRLF, Société Française d'Hématologie, Société Française de Mycologie Médicale, Société Française de Greffe de Moelle. Management of invasive candidiasis and aspergillosis in adults. Rev Pneumol Clin 2004;60:289-93.
34. Bohme A., Ruhnke M., Buchheidt D., et al. Treatment of fungal infections in hematology and oncology - guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 82 Suppl 2 (2003) S133-S140
35. Gavalda J., and Ruiz I. Guidelines for the treatment of invasive fungal infection. Invasive fungal infection by Candida spp. Invasive Fungal Infection Study Group (MICOMED) and Infection in Transplantation Study Group (GESITRA) of the Spanish Society for Infectious Diseases and Clinical Microbiology (SEIMC). Enferm Infecc Microbiol Clin 21 (2003) 498-508
36. Hospenthal D.R., Murray C.K., and Rinaldi M.G. The role of antifungal susceptibility testing in the therapy of candidiasis. Diagn Microbiol Infect Dis 48 (2004) 153-160
37. Antoniadou A., Torres H.A., Lewis R.E., et al. Candidaemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (Baltimore) 82 (2003) 309-321
38. Baddley J.W., Patel M., Jones M., Cloud G., Smith A.C., and Moser S.A. Utility of real-time antifungal susceptibility testing for fluconazole in the treatment of candidaemia. Diagn Microbiol Infect Dis 50 (2004) 119-124
39. Lee S.C., Fung C.P., Huang J.S., et al. Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole. Antimicrob Agents Chemother 44 (2000) 2715-2718
40. Nguyen M.H., Clancy C.J., Yu V.L., et al. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis 177 (1998) 425-430
41. Powderly W.G., Kobayashi G.S., Herzig G.P., and Medoff G. Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med 84 (1988) 826-832
42. Rex J.H., Pfaller M.A., Barry A.L., Nelson P.W., and Webb C.D. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidaemia. NIAID Mycoses Study Group and the Candidaemia Study Group. Antimicrob Agents Chemother 39 (1995) 40-44
43. Wenisch C., Moore C.B., Krause R., Presterl E., Pichna P., and Denning D.W. Antifungal susceptibility testing of fluconazole by flow cytometry correlates with clinical outcome. J Clin Microbiol 39 (2001) 2458-2462
44. Clancy C.J., Yu V.L., Morris A.J., Snydman D.R., and Nguyen M.H. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidaemia. Antimicrob Agents Chemother 49 (2005) 3171-3177
45. Pfaller M.A., Diekema D.J., Rex J.H., et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 44 (2006) 819-826
46. Abbas J., Bodey G.P., Hanna H.A., et al. Candida krusei fungemia. An escalating serious infection in immunocompromised patients. Arch Intern Med 160 (2000) 2659-2664
47. Bodey G.P., Mardani M., Hanna H.A., et al. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 112 (2002) 380-385
48. Safdar A., van Rhee F., Henslee-Downey J.P., Singhal S., and Mehta J. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. Bone Marrow Transplant 28 (2001) 873-878
49. Bowden R., Chandrasekar P., White M.H., et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 35 (2002) 359-366
50. Ellis M., Spence D., de Pauw B., et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 27 (1998) 1406-1412
51. Cornely O.A., Maertens J., Bresnik M., and Herbrecht R. Liposomal Amphotericin B (L-AMB) as initial therapy for invasive filamentous fungal infections (IFFI): a randomized, prospective trial of a high loading regimen vs. standard dosing (AmBiLoad Trial). Blood 106 (2005) [Abstract 3222]
52. Denning D.W., Marinus A., Cohen J., et al. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect 37 (1998) 173-180
53. Denning D.W. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 23 (1996) 608-615
54. Lin S.J., Schranz J., and Teutsch S.M. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 32 (2001) 358-366
55. Patterson T.F., Kirkpatrick W.R., White M., et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 79 (2000) 250-260
56. Walsh T.J., Goodman J.L., Pappas P., et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 45 (2001) 3487-3496
57. Cordonnier C, Bresnik M, Ebrahimi R. Liposomal amphotericin B efficacy in invasive filamentous fungal infections: Pooled analysis. In: Proceeding of the 44th interscience conference on antimicrobial agents and chemotherapy, Washington (DC), October 30-November 2; 2004 [Abstract M-1022].
58. Wingard J.R. Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. Bone Marrow Transplant 19 (1997) 343-347
59. Walsh T.J., Hiemenz J.W., Seibel N.L., et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 26 (1998) 1383-1396
60. Chandrasekar P.H., and Ito J.I. Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 40 Suppl 6 (2005) S392-S400
61. Wingard J.R., White M.H., Anaissie E., Raffalli J., Goodman J., and Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 31 (2000) 1155-1163
62. Denning D.W., Lee J.Y., Hostetler J.S., et al. NIAID Mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 97 (1994) 135-144
63. Caillot D., Bassaris H., McGeer A., et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 33 (2001) e83-e90
64. Denning D.W., Ribaud P., Milpied N., et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34 (2002) 563-571
65. Perfect J.R., Marr K.A., Walsh T.J., et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 36 (2003) 1122-1131
66. Schwartz S., Ruhnke M., Ribaud P., et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 106 (2005) 2641-2645
67. Mouas H., Lutsar I., Dupont B., et al. Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. Clin Infect Dis 40 (2005) 1141-1147
68. Steinbach W.J., Benjamin Jr. D.K., Kontoyiannis D.P., et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 39 (2004) 192-198
69. Walsh T.J., Patterson T., Langston A., et al. Posaconazole for treatment of invasive aspergillosis in patients who are refractory to or intolerant of conventional therapy: an externally controlled blinded trial. Blood 102 (2003) 195a
70. Maertens J., Raad I., Petrikkos G., et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 39 (2004) 1563-1571
71. Kartsonis N.A., Saah A.J., Joy L.C., Taylor A.F., and Sable C.A. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. J Infect 50 (2005) 196-205
72. Candoni A., Mestroni R., Damiani D., et al. Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies. Eur J Haematol 75 (2005) 227-233
73. Mukherjee P.K., Sheehan D.J., Hitchcock C.A., and Ghannoum M.A. Combination treatment of invasive fungal infections. Clin Microbiol Rev 18 (2005) 163-194
74. Aliff T.B., Maslak P.G., Jurcic J.G., et al. Refractory aspergillus pneumonia in patients with acute leukaemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 97 (2003) 1025-1032
75. Kontoyiannis D.P., Hachem R., Lewis R.E., et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 98 (2003) 292-299
76. Maertens J, Glasmacher A, Herbrecht R et al. Multicenter, noncomparative study of caspofungin combined with other antifungals in adults with invasive aspergillosis refractory or intolerant to prior therapy: final results. In: Proceeding of the 45th interscience conference on antimicrobial agents and chemotherapy, Washington (DC), December 16-19; 2005 [Abstract M-954].
77. Marr K.A., Boeckh M., Carter R.A., Kim H.W., and Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 39 (2004) 797-802
78. Mosquera J., Warn P.A., Morrissey J., Moore C.B., Gil-Lamaignere C., and Denning D.W. Susceptibility testing of Aspergillus flavus: inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin B in vitro and outcome in vivo. Antimicrob Agents Chemother 45 (2001) 1456-1462
79. Johnson E.M., Oakley K.L., Radford S.A., et al. Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection. J Antimicrob Chemother 45 (2000) 85-93
80. Odds F.C., Van Gerven F., Espinel-Ingroff A., et al. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother 42 (1998) 282-288
81. Denning D.W., Radford S.A., Oakley K.L., Hall L., Johnson E.M., and Warnock D.W. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother 40 (1997) 401-414
82. Lass-Florl C., Kofler G., Kropshofer G., et al. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J Antimicrob Chemother 42 (1998) 497-502
83. Dannaoui E., Borel E., Persat F., Piens M.A., and Picot S. Amphotericin B resistance of Aspergillus terreus in a murine model of disseminated aspergillosis. J Med Microbiol 49 (2000) 601-606
84. Walsh T.J., Petraitis V., Petraitiene R., et al. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J Infect Dis 188 (2003) 305-319